<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/636e/5593693/67f573a0a743/oncotarget-08-57898-g002.jpg"/> </div> <div class="text-side"> <h1>Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.</h1> <p>Pathological examinationH&amp;E staining (×400) showed some pink cytoplasm with distinct cell borders and intercellular bridges characteristic A. Immunohistochemical results show thatP63 B., Ki67 C. and CK516 D. are positive (×400).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28915721/" target="_blank">28915721</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>